Search Results - tils

3 Results Sort By:
Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy
Description of Technology: Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL), T cell receptor (TCR) and Chimeric Antigen Receptor (CAR) engineered T cells, or hematopoietic stem cell transplantation, is a promising new approach to cancer treatment. ACT harnesses an individual's adaptive immune system to fight against cancer,...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Warren Leonard, Dalton Hermans, Luca Gattinoni, Leonard Neckers
Keywords(s): act, Adoptive T Cell Therapy, CAR T Cells, CD8+ T Cells, Gattinoni, Interleukin-21, Lactate Dehydrogenase Inhibitor, LDH, Neckers, Preconditioning, TCR-engineered T Cells, TILS
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics
Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients
Summary: NCI seeks commercial partners to co-develop and/or license a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL). Description of Technology: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize antigens expressed by cancer cells...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Rami Yoseph, Paul Robbins, Frank Lowery, Sri Krishna, Amy Copeland, Steven Rosenberg
Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptors, TCRs, TILS, Tumor Infiltrating Lymphocytes
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy
Summary: The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies. Description of Technology: Adoptive T-cell therapy (ACT) utilizes tumor-reactive T cells to induce disease remission. While ACT has been used effectively to treat metastatic melanoma and certain epithelial...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Steven Rosenberg, Gregoire Altan-Bonnet, Sri Krishna, Paul Robbins, Frank Lowery
Keywords(s): act, Adoptive T Cell Therapy, Cancer Immunotherapies, CAR, CD-39 Receptor, CD3-Receptor, CD-69 Receptor, chimeric antigen receptor, Lowery, Rosenberg, T Cell Receptor, TCR, TILS, Tumor-Infiltrating T-Lymphocytes
Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics